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Wingless-type (Wnt) signaling through the secretion of
Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2
and -3 has a key role in the decreased osteoblast (OB) activity
associated with multiple myeloma (MM) bone disease. We
provide evidence that another Wnt antagonist, sclerostin, an
osteocyte-expressed negative regulator of bone formation, is
expressed by myeloma cells, that is, human myeloma cell lines
(HMCLs) and plasma cells (CD138þ cells) obtained from the
bone marrow (BM) of a large number of MM patients with bone
disease. We demonstrated that BM stromal cells (BMSCs),
differentiated into OBs and co-cultured with HMCLs showed,
compared with BMSCs alone, reduced expression of major
osteoblastic-speciﬁc proteins, decreased mineralized nodule
formation and attenuated the expression of members of the
activator protein 1 transcription factor family (Fra-1, Fra-2 and
Jun-D). Moreover, in the same co-culture system, the addition
of neutralizing anti-sclerostin antibodies restored OB functions
by inducing nuclear accumulation of b-catenin. We further
demonstrated that the upregulation of receptor activator of
nuclear factor j-B ligand and the downregulation of osteopro-
tegerin in OBs were also sclerostin mediated. Our data
indicated that sclerostin secretion by myeloma cells contribute
to the suppression of bone formation in the osteolytic bone
disease associated to MM.
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Introduction
Multiple myeloma (MM) is a hematological B-cell malignancy
that results from the clonal expansion of plasma cells within
bone marrow (BM), mostly with overproduction of monoclonal
immunoglobulins.
1–3 Symptomatic MM is deﬁned by the
evidence of end-organ or tissue damage attributable to plasma
cell proliferation according to the CRAB criteria, that consist
of C: hypercalcemia (411.5mg/dl); R: renal failure (serum
creatinine 4173mmol/l); A: anemia (hemoglobin o10g/dl or
2g/dl below the lower limit of normal); and B: bone disease
(lytic lesions, severe osteopenia or pathological fractures).
2,3
Symptomatic MM needs appropriate therapy, and it is differ-
entiated from monoclonal gammapathy of undetermined
signiﬁcance (MGUS) and asymptomatic (smoldering) MM based
on the presence or absence of end-organ damage. The staging of
symptomatic MM according to the International Staging System
(ISS) is based on two laboratory tests, serum levels of
b2-microglobulin and albumin, and it divides patients into three
distinct stages with different outcomes.
4 MM bone disease has a
major impact on patient morbidity and mortality. Myeloma cell
has a pivotal role in the pathogenetic mechanism of MM bone
disease, which is characterized by an increased osteoclastic
bone resorption accompanied by a suppressed osteoblastic
function.
1 Osteoclastogenesis is regulated by a signaling path-
way, involving both receptor activator of nuclear factor-kB
(RANK) expressed on the surface of mature osteoclasts and their
precursors, and RANK ligand (RANKL) expressed on BM stromal
cells (BMSCs).
5 In addition, osteoprotegerin (OPG), a soluble
decoy receptor secreted by osteoblasts (OBs) and BMSCs,
competes with RANK for binding to RANKL, resulting in
an anti-osteoclastogenic effect. Myeloma cell stimulates
osteoclastogenesis by triggering both RANKL increase and
OPG reduction.
6–8
Osteoblastogenesis involves the differentiation of BMSCs into
functional OBs, implicating the activation of different transcrip-
tion factors such as Cbfa1/Runx2, which directly regulates the
expression of the major OB markers such as collagen type I
(COLL I), osteopontin, bone sialoprotein II (BSP II) and
osteocalcin (OSTC).
9,10 Another relevant transcription factor is
the activator protein 1 (AP-1), which consists of multiple dimers
of proteins belonging to Fos (c-Fos, FosB, Fra-1 and Fra-2) and
Jun families (c-Jun, JunB and JunD).
11 Mice with conditional
deletion of fra-1 develop osteopenia, that seems to be due to the
reduced expression of bone matrix genes encoding for OSTC,
COLL I and matrix Gla protein.
12 Recently a direct transcrip-
tional regulation of genes encoding for COLL I and OSTC by
Fra-2 in human has been demonstrated.
13 One of the most
relevant signaling regulating OB differentiation is represented by
the canonical Wingless-type (Wnt) pathway. Wnts are secreted
cysteine-rich glycoproteins known as regulators of hematopoie-
tic and mesenchymal cell differentiation as well as of embryonic
development.
14–16 The activation of canonical Wnt signaling,
induced by binding of Wnt proteins to both Frizzled receptor
and low-density lipoprotein receptor-related protein (LRP-5/6)
co-receptor, is followed by b-catenin translocation into the
nucleus,
17,18 resulting in the activation of major OB transcrip-
tion factors. Wnt pathway is tightly regulated by several secreted
antagonists, that is, soluble frizzled-related proteins (sFRPs),
which interfere with Wnt/Frizzled receptor binding, or Dickkopf
(DKK) proteins and sclerostin, which bind the co-receptor
LRP5/6.
19 The OB suppression occurring in MM bone disease
has been related to the inhibition of the canonical
Wnt signaling, through DKK1 (ref. 20) and sFRP-2 and -3 (refs
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Sclerostin, the product of SOST gene, is prominently produced
by osteocytes embedded in newly formed bone.
25 In mouse,
sclerostin has been reported to inhibit the differentiation and
mineralization of preosteoblastic cells.
26,27 In humans, muta-
tions in the SOST gene cause sclerosing bone dysplasia, such as
sclerosteosis and Van Buchem disease,
28–30 related to increased
bone formation. Recently, studies on these two rare bone
disorders led to the identiﬁcation of sclerostin as an important
negative regulator of bone formation. Further, the ongoing
development of new therapeutic approaches for reduced bone
mass diseases spans antibodies against Wnt antagonists, includ-
ing sclerostin.
31,32 Here we studied sclerostin involvement in
the impaired bone formation of MM bone disease.
Patients and methods
Patients
The samples consisted of BM aspirates from the iliac crest from
60 patients (mean age, 68 years; range, 55–87 years) newly
diagnosed as having active symptomatic MM,
3 requiring therapy
in accordance with the International Myeloma Working Group
criteria
2,3 and classiﬁed according to ISS.
4 A total of 43 of such
patients showed radiological evidence of bone involvement,
including osteolysis, osteoporosis, pathological fractures, spinal
cord compression and plasmacytoma. Some patients deserved
magnetic resonance imaging or computerized tomography to
assess the symptomatic bony sites with negative skeletal survey,
suspected cord compression or size of tumor mass. The controls
included BM aspirates from 38 subjects with MGUS without
evidence of bone disease, matched for age and sex with the
patients diagnosed as having MM. Informed consent to the study
was given according to the tenets of the Declaration of Helsinki.
Approval was obtained from the Institutional Review Board of
the Department of Internal Medicine and Public Medicine of
University of Bari.
Cells
Human myeloma cell lines (HMCLs) and CD138þ
cells. HMCLs (H929, RPMI 8226, U266 and Karpas 929) were
cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (Gibco Invitrogen, Milan, Italy). Malignant plasma
cells from BM aspirates of patients (MM plasma cells) and
controls, identiﬁed as CD138þ cells, were carried out with a
magnetic cell-sorting separator (Miltenyi Biotec, Bergisch-
Gladbach, Germany) using magnetic microbeads (Miltenyi
Biotec) coupled to anti-CD138 monoclonal antibody (mAb).
Only samples with a purity of more than 97%, checked by ﬂow
cytometry, were considered. Fresh CD138þ cells were used for
RNA or protein extraction, or co-culture experiments.
Human BM cells. BM aspirates of MGUS controls were
subjected to Histopaque 1077 density gradient (Sigma Aldrich,
St Louis, MO, USA). The buffy coat cell fraction was entirely
cultured to obtain the BM mononuclear cells (BMNCs) used in
colony-forming unit-ﬁbroblast (CFU-F) and colony-forming
unit-OB (CFU-OB) assays. BMSCs were obtained from adherent
fraction of BMNCs and used in co-culture experiments.
Cell culture conditions and co-cultures
BMNCs were plated at the density of 4 10
5/cm
2 in an OB
differentiating medium, consisting of a-minimum essential
medium supplemented with 10% fetal bovine serum, 50mg/ml
ascorbic acid and 10
 8 M dexamethasone (Sigma Aldrich).
These cells were co-cultured with 1 10
5/cm
2 HMCLs or
CD138þ cells from symptomatic MM patients, or puriﬁed B
lymphocytes from normal donors. All experiments of co-culture
were performed in the absence or in the presence of 50 and
500ng/ml neutralizing anti-sclerostin mAb (R&D Systems,
Minneapolis, MN, USA), or anti-immunoglobulin G (IgG)
control Ab. These co-cultures were maintained in OB differ-
entiating medium for 21 days to evaluate the formation of
CFU-F, identiﬁed as alkaline phosphatase-positive colonies. In
parallel, we maintained the co-cultures in osteogenic medium,
consisting of OB-differentiating medium supplemented with
10mM b-glycerophosphate, for 30 days to evaluate the
formation of CFU-OB, identiﬁed with Von Kossa staining.
33
Moreover, we also performed in OB-differentiating medium
short-term (48h) co-cultures and in osteogenic medium long-
term (30 days) between semiconﬂuent BMSCs and HMCLs, or
CD138þ cells from symptomatic MM patients, or B lympho-
cytes. We analyzed in the former co-cultures the expression
of COLL I, RANKL, OPG, Runx2, Osterix, Fra-1, Fra-2, JunD,
b-catenin and sclerostin–LRP-5/6 immunocomplex, and in the
latter co-cultures the expression of BSP II and OSTC. In these
experiments, HMCLs or CD138þ cells were removed using
magnetic cell-sorting separator, whereas B lymphocytes were
removed using a positive immunoselection with anti-CD19 mAb
(Dynal, Lake Success, NY, USA), and the BMSCs were subjected
to RNA or protein extraction. BMSC viability was performed
as previously described
8 to exclude any toxic or apoptotic effect
induced by HMCLs in the co-culture system.
RNA isolation and real-time PCR ampliﬁcation
RNA from CD138þ cells, HMCLs and BMSCs was extracted
and subjected to real-time PCR as previously described.
8
Appropriate primer pairs were used for the PCR ampliﬁcation.
Western blot analysis and immunoprecipitation
Western blot analysis and immunoprecipitation were performed
as previously described.
8 The following primary Abs were used:
polyclonal anti-COLL I, anti-BSP-II, anti-Fra-2, anti-JunD, anti-
OPG, anti-Lamin B1, anti-ERK1/2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-RANKL (R&D Systems) and anti-b-
catenin (Cell Signaling Technology, Danvers, MA, USA);
monoclonal anti-b-actin, anti-Fra-1 (Santa Cruz Biotechnology),
and anti-sclerostin (R&D Systems).
Statistical analyses
Statistical analyses were performed by Student t-test with the
Statistical Package for the Social Sciences (spssx/pc) software
(SPSS, Chicago, IL, USA).
Results
Expression of sclerostin by HMCLs or CD138þ
cells from patients
By means of real-time PCR or western blot analysis, we
determined the expression of sclerostin by four HMCLs (that
is, H929, RPMI-8226, U266 and Karpas 909) or by freshly
puriﬁed CD138þ cells from BM aspirates of both MM patients
and controls. Owing to the low number of CD138þ cells
obtained in individual BM aspirates, the expression of sclerostin
from each donor could only be assessed at mRNA or at protein
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Blood Cancer Journallevel. By real-time PCR, the lowest level of sclerostin mRNA was
found in controls, whereas it was several folds higher in almost
all MM patients in which higher levels were detected when
bone disease was evident. However, it should be noted that in
some cases an overlap of sclerostin mRNA levels between
symptomatic MM patients both with and without bone disease
and controls was observed.
Among the HMCLs, H929 expressed signiﬁcant high mRNA
levels of sclerostin (Figure 1a). By western blots, we determined
that sclerostin was much strongly expressed in MM bone disease
patients, whereas it was undetectable in the controls. In the four
HMCLs, sclerostin was well evident at protein levels with the
highest amount in H929 (Figure 1b). Of note, although
increased mRNA levels of sclerostin were only detected
in some samples either from patients (8/20) or HMCLs (1/4),
all samples from symptomatic MM with bone disease as well
as all HMCLs expressed sclerostin at protein level (Figure 1b).
An overview of clinical characteristics of symptomatic MM
patients and sclerostin expression has been reported in
Supplementary Table 1.
CFU-F and CFU-OB formation in co-cultures of BMNCs
and HMCLs or CD138þ cells from patients
On the basis of our ﬁndings on the sclerostin expression by
myeloma cells, we investigated whether this protein could
impair OB differentiation. We performed long-term co-cultures
(allowing cell-cell contacts) of BMNCs from MGUS controls and
H929 in the presence or in the absence of 50 and 500ng/ml
anti-sclerostin mAb. The formation of CFU-F or CFU-OB was
assessed as indicator of early or late phase of OB differentiation,
respectively. The results were compared with those obtained by
culturing BMNCs alone. We found that H929 signiﬁcantly
inhibited CFU-F formation after 21 days (Figure 2a), and the
formation of CFU-OB after 30 days (Figure 2b). The addition
of anti-sclerostin mAb at two different concentrations partially
restored CFU-F and CFU-OB formation (Figures 2a and b). As
reported in Supplementary Table 2, all HMCLs exhibited
comparable results. Similarly, CD138þ cells from symptomatic
MM patients inhibited the formation of both CFU-F and CFU-OB
respect to BMNCs alone, and this inhibition was partially
rescued in the presence of anti-sclerostin mAb (Figures 2a and
b). These data suggest a sclerostin involvement in the inhibition
of OB differentiation. Conversely, B lymphocytes did not inhibit
the formation of CFU-F and CFU-OB (data not shown).
Expression of OB differentiation markers in
BMSCs co-cultured with HMCLs
By using the same co-culture system, we investigated whether
myeloma cells could impair, through sclerostin production,
speciﬁc parameters of OB differentiation such as production of
extracellular bone matrix proteins. By western blots, we found a
strong inhibition of COLL I synthesis in a sclerostin-dependent
manner in short-term co-cultures. Indeed, the results were
partially reverted by the addition of 50ng/ml anti-sclerostin
mAb, and totally reverted by 500ng/ml mAb (Figure 3Aa).
In long-term co-cultures, we also demonstrated a signiﬁcant
reduction of BSP II and OSTC, which are expressed during the
late phase of OB differentiation. BSP II was detected at protein
levels (Figure 3Ab), and OSTC at mRNA level (Figure 3Ac). In
the presence of 50 and 500ng/ml anti-sclerostin mAb, there was
a partial rescue, clearly indicating a role for sclerostin. In
particular, the effect on BSP II expression appeared to be almost
the same at both mAb concentrations (Figure 3Ab), whereas the
effect on OSTC expression was observed in the presence of
500ng/ml mAb (Figure 3Ac). In both the short- and long-term
co-cultures, the inhibition of the OB marker synthesis exerted by
CD138þ cells from symptomatic MM patients or by all the
other HMCLs as well as the effect of the mAb was quite
Figure 1 Expression of sclerostin by HMCLs or CD138þ cells from patients. CD138þ cells from controls and symptomatic MM patients with or
without bone disease as well as HMCLs were studied for sclerostin expression at mRNA (a) and protein levels (b). The lowest mRNA levels of
sclerostin were found in the controls; in comparison with these, sclerostin mRNA levels were 2.9-fold (Po0.0001) increased in MM patients
without bone disease, and 4.43-fold (Po0.0001) increased in MM patients with bone disease. Among HMCLs, the higher expression of sclerostin
at mRNA level was detected in H929 (a). By western blot analysis, higher protein levels of sclerostin were detected in MM patients with bone
disease than in those without bone disease, whereas control samples did not display detectable amount. Sclerostin expression was also detected in
HMCLs at protein level (b). BD, bone disease; ERK, extracellular signal-regulated kinase; w/o, without.
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not affected by anti-IgG Ab or B-lymphocytes (data not shown).
Any toxic- or apoptotic-induced effect of HMCLs on OB cultures
was excluded by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay.
Expression of OB transcription factors in BMSCs
co-cultured with HMCLs
On the basis of results obtained on bone protein expression, we
evaluated whether myeloma cells could affect, through scler-
ostin, the expression of transcription factors tightly regulating
OB differentiation, such as Runx2, Osterix and AP-1. By using
the same co-culture system, we show that the presence of H929
induced a reduced expression of the dimeric AP-1 complex in
BMSCs due to the decreased expression of Fra-1, Fra-2 and
JunD. Fra-1 and JunD were rescued in a dose–response manner
by anti-sclerostin mAb added to the system, whereas Fra-2
expression was only partially rescued, even in the presence of
the highest mAb concentration (Figure 3B). The inhibition of the
OB transcription factors exerted by CD138þ cells from
symptomatic MM patients or by all the other HMCLs was quite
comparable; conversely anti-IgG Ab or B-lymphocytes did not
affect the expression of such factors (data not shown).
Expression of RANKL and OPG by BMSCs
co-cultured with HMCLs
On the basis of the knowledge that RANKL/OPG ratio can be
unbalanced by Wnt inhibitors,
34 we investigated whether in our
co-culture system myeloma cells could affect, through sclerostin
production, the expression of these cytokines, respectively with
pro- and anti-osteoclastogenic activity. H929 upregulated
RANKL and strongly downregulated OPG expression by BMSCs
in a sclerostin-dependent manner. In fact these effects were
progressively reverted in the presence of anti-sclerostin mAb
(Figure 3C). Both CD138þ cells from symptomatic MM patients
and all the other HMCLs similarly inﬂuenced RANKL and OPG
expression, conversely their levels were not affected by anti-IgG
Ab or B-lymphocytes (data not shown).
Formation of the LRP5/6–sclerostin complex and
nuclear b-catenin accumulation in BMSCs co-cultured
with HMCLs
To investigate whether myeloma cells might affect the canonical
Wnt signaling in BMSCs, we evaluated in our co-culture system
the formation of LRP5/6–sclerostin complex and the nuclear
accumulation of b-catenin. The formation of this complex is
followed by the inhibition of Wnt signaling, whereas the
Figure 2 CFU-F and CFU-OB formation in BMNCs co-cultured with H929 or CD138þ cells from patients. CFU-F (a) and CFU-OB (b) formation
have been determined in co-cultures between BMNCs and H929 or CD138þ cells from symptomatic MM patients (þ) in the absence ( ) or in the
presence of 50 or 500ng/ml anti-sclerostin mAb. The results were compared with those obtained when BMNCs were cultured alone. H929 or
CD138þ cells from symptomatic MM patients signiﬁcantly inhibited both CFU-F (a) and CFU-OB (b) formation, which were increased in the
presence of 50 and 500ng/ml anti-sclerostin mAb. The graphs represent the mean number of CFU-F/well or CFU-OB/well ±S.E. of six
independent experiments performed in triplicate.
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activation. In the presence of H929, we detected the formation
of LRP5/6–sclerostin complex, which was proportionally
reduced in the presence of anti-sclerostin mAb at the two
different concentrations (Figure 4a). Moreover, HMCLs pre-
vented b-catenin accumulation in BMSC nuclei and this effect
was slightly inﬂuenced by anti-sclerostin mAb only at the
concentration of 500ng/ml (Figure 4b). MM plasma cells and
all HMCLs induced the formation of the LRP5/6–sclerostin
complex, and inhibited the accumulation of nuclear b-catenin
in a comparable way. Differently, in the presence of an
anti-IgG Ab or B lymphocytes, no effect was seen on both the
LRP5/6–sclerostin complex formation and the nuclear b-catenin
accumulation (data not shown).
Discussion
Bone disease is the most characteristic marker of end-organ or
tissue damage in MM. It has been demonstrated that myeloma
cell disrupts the balance between osteoclastic bone resorption
and osteoblastic bone formation. Increased osteoclastic activity
is mainly due to MM-induced RANKL and other osteoclasto-
genic cytokines,
1,7,8 whereas OB suppression involves a number
of Wnt inhibitors, such as DKK1, sFRP-2 and -3.
1,20–23 Sclerostin
is another molecule inhibiting Wnt signaling, whose expression
is restricted to bone tissue. High serum levels of sclerostin were
reported in long-term immobilized patients,
35 and in ankylosing
spondylitis.
36 However, there are no data on its role in MM bone
disease, except for data presented by Terpos et al.
24 at the last
Figure 3 Expression of OB differentiation markers, transcription factors, RANKL and OPG in BMSCs co-cultured with H929. Co-cultures were
performed with BMSCs and H929 (þ) in the absence ( ) or in the presence of 50 or 500ng/ml anti-sclerostin mAb. H929 inhibited the expression
of protein levels of COLL I (Aa), BSP II (Ab) and mRNA levels of OSTC (Ac) in BMSCs. The inhibition was partially rescued
by the mAb. H929 also inhibited Fra-1 (Bd), Fra-2 (Be) and JunD (Bf) expression at protein level and the partial abrogation of these effects was
observed in the presence of mAb. Moreover, the presence of H929 increased RANKL (Cg) and decreased OPG (Ch) expression. These effects were
partially rescued by the presence of the mAb, as showed by histograms reporting the intensity of the bands quantiﬁed by densitometry and
normalized to b-Actin.
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sclerostin serum levels with ISS-3 disease in newly diagnosed
patients with MM. The aim of our study was to understand
whether sclerostin has a role in MM bone disease. We
demonstrate that it is expressed by myeloma cells isolated from
patients with MM bone disease and that, although its mRNA
expression does not always correlate with the extent of bone
damage, sclerostin protein levels seem to be associated with the
severity of their disease. This was identiﬁed by the evidence of
pathological fractures, cord compression or plasmacytoma, as
well as by the concomitant renal impairment and/or anemia and
ISS-2 or ISS-3 disease. Otherwise, low mRNA levels of sclerostin
and undetectable amount of the protein were assessed in MGUS
patients. Of note, no progression to MM was detected in these
control subjects until the time of the writing. Accordingly, we
demonstrate, by means of an in vitro model consisting of a
co-culture of BMSCs isolated from MGUS controls and HMCLs
or CD138þ cells, that the OB suppression observed in
co-cultures in the presence of myeloma cells is largely sclerostin
dependent. In fact, OB inhibition could be partially restored by
the addition of a neutralizing anti-sclerostin mAb. The OB
inhibition resulted in a reduced expression of OB functional
differentiation markers, as ALP and COLL I in short-term co-
cultures, and BSP II, OSTC and mineralized nodule formation in
long-term co-cultures. The OB inhibiting effect exerted by
myeloma cells on OB activity has been already described,
21,23
but the partial rescue of OB formation and activity, obtained by
the addition of anti-sclerostin mAbs, indicates the involvement
of sclerostin among other Wnt inhibitors. This is consistent with
literature data in which the involvement of DKK1 and sFRP-2
and -3 is demonstrated.
20–23
The genes belonging to AP-1 complex, Fra-1, Fra-2 and Jun-D
have a key role in controlling OB differentiation, and were
downregulated in our co-cultures. These genes, in particular, the
inhibition of Fra-1 in our system could be responsible for
the reduction of COLL I and OSTC. Indeed, Fra-1 is critical in
the regulation of bone matrix genes encoding for COLL I and
OSTC.
12 In addition, the inhibition of Fra-2 and Jun D, whose
expression is prominent in differentiating OBs,
37 could be
responsible for the reduced formation of mineralized nodules.
However, recently a direct Fra-2 transcriptional regulation of
COLL I and OSTC genes in humans has been demonstrated,
13
suggesting a possible involvement of both Fra-1 and Fra-2 in all
the differentiation phases of OBs. In our system, the implication
of sclerostin in the inhibition of Fra-1, Fra-2 and JunD was
evident from the partial rescue of their expression in the
presence of neutralizing anti-sclerostin mAbs.
The role played by sclerostin in the suppression of OB
function is also supported by our ﬁndings concerning
the formation of LRP5/6–sclerostin complex, as well as the
inhibition of b-catenin translocation into OB nuclei: the former
abolished and the latter partially restored by the addition of the
anti-sclerostin mAbs. Our ﬁndings are consistent with the
literature data,
23 demonstrating a signiﬁcantly reduced translo-
cation of b-catenin into the OB nuclei in the presence of
myeloma cells. Wnt pathway also regulates osteoclast formation
and resorption modulating the expression of both RANKL and
OPG in OBs.
34 Consistently, we demonstrated that sclerostin
mediated the upregulation of RANKL and the downregulation of
OPG in our co-culture system.
In conclusion, our ﬁndings demonstrate for the ﬁrst time the
expression of sclerostin by myeloma cells and its association
with the advanced ISS of the disease. Furthermore, sclerostin
contribution in the development of MM bone disease could be
related to both a direct induction of OB suppression with
reduced bone formation, and an indirect activation of osteoclast
bone resorption through the unbalanced RANKL/OPG ratio.
Thus, sclerostin can provide a promising potential target for the
development of novel therapeutics to rebuild bone mass in MM
bone disease.
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